You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 26, 2024

Meropenem - Generic Drug Details

✉ Email this page to a colleague

« Back to Dashboard

What are the generic sources for meropenem and what is the scope of freedom to operate?

Meropenem is the generic ingredient in four branded drugs marketed by Acs Dobfar, Acs Dobfar Spa, Amneal Pharms, Brooks Steriscience, Daewoong Pharm Co, Eugia Pharma, Gland, Hospira Inc, Hq Spclt Pharma, Sandoz, Savior Lifetec Corp, Pfizer, B Braun Medical Inc, and Rempex, and is included in fifteen NDAs. There are seven patents protecting this compound. Additional information is available in the individual branded drug profile pages.

There are thirty-two drug master file entries for meropenem. Thirteen suppliers are listed for this compound.

Summary for meropenem

US Patents:	7
Tradenames:	4
Applicants:	14
NDAs:	15
Drug Master File Entries:	32
Finished Product Suppliers / Packagers:	13
Raw Ingredient (Bulk) Api Vendors:	84
Clinical Trials:	131
Patent Applications:	7,455
Formulation / Manufacturing:	see details
Drug Prices:	Drug price trends for meropenem
What excipients (inactive ingredients) are in meropenem?	meropenem excipients list
DailyMed Link:	meropenem at DailyMed

See drug prices for meropenem

Recent Clinical Trials for meropenem

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Antabio	Phase 1
Wake Forest University Health Sciences	Phase 4
Assistance Publique - Hôpitaux de Paris	Phase 4

See all meropenem clinical trials

Pharmacology for meropenem

Drug Class	Penem Antibacterial

Anatomical Therapeutic Chemical (ATC) Classes for meropenem

J01DH	Carbapenems
J01D	OTHER BETA-LACTAM ANTIBACTERIALS
J01	ANTIBACTERIALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

US Patents and Regulatory Information for meropenem

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Rempex	VABOMERE	meropenem; vaborbactam	POWDER;INTRAVENOUS	209776-001	Aug 29, 2017		RX	Yes	Yes	⤷ Try a Trial	⤷ Try a Trial				⤷ Try a Trial
Acs Dobfar	MEROPENEM	meropenem	INJECTABLE;INJECTION	091404-002	Oct 26, 2011	AP	RX	No	No	⤷ Try a Trial	⤷ Try a Trial				⤷ Try a Trial
Eugia Pharma	MEROPENEM	meropenem	INJECTABLE;INJECTION	205835-001	Mar 27, 2017	AP	RX	No	No	⤷ Try a Trial	⤷ Try a Trial				⤷ Try a Trial
Sandoz	MEROPENEM	meropenem	INJECTABLE;INJECTION	091201-001	Mar 29, 2011		DISCN	No	No	⤷ Try a Trial	⤷ Try a Trial				⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for meropenem

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pfizer	MERREM	meropenem	INJECTABLE;INJECTION	050706-001	Jun 21, 1996	⤷ Try a Trial	⤷ Try a Trial
Pfizer	MERREM	meropenem	INJECTABLE;INJECTION	050706-003	Jun 21, 1996	⤷ Try a Trial	⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.